Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

244

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

July 1, 2028

Study Completion Date

July 1, 2028

Conditions
Endometrial Cancer
Interventions
DRUG

carboplatin and paclitaxel

6 courses of iv 3-weekly chemotherapy Carboplatin AUC5 Paclitaxel 175mg/m2

OTHER

observation

active observation

Trial Locations (1)

2100

Danish Gynecological Cancer Group (DGCG), Copenhagen

All Listed Sponsors
collaborator

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

collaborator

Arbeitsgemeinschaft Gynaekologische Onkologie Austria

OTHER

collaborator

North Eastern German Society of Gynaecological Oncology

OTHER

collaborator

Nordic Society of Gynaecological Oncology - Clinical Trials Unit

OTHER

collaborator

Belgian Gynaecological Oncology Group

OTHER

collaborator

Mario Negri Gynecologic Oncology group (MaNGO)

OTHER

collaborator

Israeli Society of Gynecologic Oncology

OTHER

collaborator

Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO)

UNKNOWN

collaborator

Central and Eastern European Oncology Group

OTHER

lead

Danish Gynecological Cancer Group

NETWORK

NCT01244789 - Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer | Biotech Hunter | Biotech Hunter